- Home
- ABOS vs RGC Comparison
ABOS vs RGC Comparison
Compare ABOS & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.15
HOLD
Current Price
$19.62
Company Overview
Basic Information| Metric | ABOS | RGC |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.9M | 9.8B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ABOS | RGC |
|---|---|---|
| Price | $2.15 | $19.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.67 | N/A |
| AVG Volume (30 Days) | 155.0K | ★ 238.7K |
| Earning Date | 11-12-2025 | 10-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $0.09 |
| 52 Week High | $2.46 | $83.60 |
Technical Indicators
Market Signals| Indicator | ABOS | RGC |
|---|---|---|
| Relative Strength Index (RSI) | 59.19 | 72.64 |
| Support Level | $2.01 | $16.30 |
| Resistance Level | $2.15 | $18.10 |
| Average True Range (ATR) | 0.13 | 1.72 |
| MACD | 0.03 | 0.53 |
| Stochastic Oscillator | 73.58 | 98.55 |
Price Performance
Historical Comparison ABOS
RGC
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.